DE4090565T - - Google Patents

Info

Publication number
DE4090565T
DE4090565T DE19904090565 DE4090565T DE4090565T DE 4090565 T DE4090565 T DE 4090565T DE 19904090565 DE19904090565 DE 19904090565 DE 4090565 T DE4090565 T DE 4090565T DE 4090565 T DE4090565 T DE 4090565T
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19904090565
Other languages
German (de)
Other versions
DE4090565C2 (de
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DE4090565T publication Critical patent/DE4090565T/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19904090565 1989-04-17 1990-04-16 Pending DE4090565T (show.php)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33900489A 1989-04-17 1989-04-17
US39448889A 1989-08-16 1989-08-16
US07/502,834 US5338683A (en) 1981-12-24 1990-04-04 Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins

Publications (1)

Publication Number Publication Date
DE4090565T true DE4090565T (show.php) 1992-05-14

Family

ID=27407304

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19904090565 Pending DE4090565T (show.php) 1989-04-17 1990-04-16
DE4090565A Expired - Lifetime DE4090565C2 (de) 1989-04-17 1990-04-16 Rekombinantes Herpesvirus-Pockenvirus-Vakzin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE4090565A Expired - Lifetime DE4090565C2 (de) 1989-04-17 1990-04-16 Rekombinantes Herpesvirus-Pockenvirus-Vakzin

Country Status (17)

Country Link
US (3) US5338683A (show.php)
JP (2) JP3083839B2 (show.php)
KR (1) KR920700289A (show.php)
AT (1) AT405184B (show.php)
AU (1) AU625623B2 (show.php)
BE (1) BE1004369A5 (show.php)
CA (1) CA2014465C (show.php)
CH (1) CH682671A5 (show.php)
DE (2) DE4090565T (show.php)
DK (1) DK176464B1 (show.php)
FR (1) FR2647808B1 (show.php)
GB (1) GB2246784B (show.php)
IE (1) IE61098B1 (show.php)
IT (1) IT1241119B (show.php)
LU (1) LU88018A1 (show.php)
NL (1) NL195016C (show.php)
WO (1) WO1990012882A1 (show.php)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
KR100372934B1 (ko) * 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0561034B1 (en) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
EP0538496B1 (en) * 1991-08-26 2003-10-29 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
AU6299594A (en) * 1993-02-26 1994-09-14 Nippon Zeon Co., Ltd. Recombinant fowlpox virus s-fpv-043 and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US6010703A (en) * 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
CA2182888C (en) * 1994-03-30 2007-08-07 Enzo Paoletti Nucleotide and amino acid sequences of canine herpesvirus gb, gc and gd and uses therefor
ATE298370T1 (de) * 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
JP4741074B2 (ja) 1998-02-24 2011-08-03 シスターズ オブ プロビデンス イン オレゴン Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法
AU759603B2 (en) 1998-02-27 2003-04-17 Trustees Of The University Of Pennsylvania, The Vaccines, immunotherapeutics and methods for using the same
CA2359075A1 (en) 1999-02-19 2000-08-24 Michigan State University An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
KR20070053815A (ko) 1999-03-03 2007-05-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법
ATE464910T1 (de) 1999-04-30 2010-05-15 Univ Pennsylvania Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
US6355246B1 (en) 1999-06-10 2002-03-12 Board Of Trustees Of Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
BR0011732B1 (pt) * 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
EP1207889A4 (en) 1999-09-02 2004-05-19 Univ Michigan State VACCINE FOR COMBATING EQUINE MYELOENCEPHALITIS IN PROTOZOA
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
DE60038048T2 (de) * 1999-12-21 2009-07-09 Merial Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe
DE60134408D1 (de) * 2000-07-14 2008-07-24 Univ Pennsylvania Für akzessorische hiv proteine kodierende dna impfstoffe
AU2002211524B2 (en) * 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CA2421151C (en) * 2000-11-23 2013-07-02 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
AU2002255995A1 (en) * 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
WO2002100317A2 (en) * 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7135562B2 (en) * 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
CN100540051C (zh) * 2002-04-19 2009-09-16 巴法里安诺迪克有限公司 用于接种新生儿的改良的安卡拉痘苗病毒
PL216760B1 (pl) * 2002-05-16 2014-05-30 Bavarian Nordic As Rekombinowany modyfikowany wirus krowianki Ankara oraz sposób jego otrzymywania i zastosowania
MXPA04012966A (es) * 2002-09-05 2005-05-16 Bavarian Nordic As Metodo para el cultivo de celulas primarias y para la amplificacion de virus bajo condiciones libres de suero.
US20040170646A1 (en) * 2002-12-13 2004-09-02 Aventis Pasteur, Inc. Production of ALVAC on avian embryonic stem cells
CN1980571A (zh) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 禽类及禽蛋中表达的外源蛋白质
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1633372B1 (en) 2003-06-13 2011-11-30 The Trustees of The University of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
CA2545886A1 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
US20050202484A1 (en) 2004-02-19 2005-09-15 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
WO2007050095A2 (en) * 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
CN101223187A (zh) 2004-11-24 2008-07-16 萨拉普托斯股份公司 用作双重胱天蛋白酶-2/-6抑制剂的新肽及其生物学应用
US20080064862A1 (en) * 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
DK1881845T3 (da) 2005-04-25 2010-06-07 Merial Ltd Nipah-virusvacciner
MX2008001326A (es) * 2005-07-28 2008-03-19 Pfizer Prod Inc Procedimientos de administracion de vacunas, nuevos calicivirus felinos, y tratamientos para inmunizar animales contra paraovirus felino y herpes virus felino.
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
US8178660B2 (en) 2006-01-13 2012-05-15 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized IL-15 and methods for using the same
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
NZ571459A (en) 2006-03-29 2011-09-30 Merial Ltd Vaccine against streptococcus equi
CA2670804A1 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur Inc. Immunological composition
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008014521A2 (en) 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
SI2147105T1 (sl) 2007-05-02 2013-08-30 Merial Limited DNA-plazmidi z izboljšano ekspresijo in stabilnostjo
TW200907058A (en) 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
CN105535961A (zh) 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
EP2274442B1 (en) * 2008-04-04 2016-06-29 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
AU2008363596B2 (en) 2008-10-29 2015-04-30 Inovio Pharmaceuticals, Inc Improved HCV vaccines and methods for using the same
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
WO2010127115A1 (en) 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2011032179A1 (en) 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
CN102712931A (zh) 2009-11-02 2012-10-03 宾夕法尼亚大学托管会 口蹄疫病毒病毒(fmdv)共有蛋白质、其编码序列及由其制备的疫苗
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
JP6125232B2 (ja) 2010-02-08 2017-05-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｒａｎｔｅｓをコードする核酸分子、ならびにこれを含む組成物およびこれを用いる方法
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
KR102131276B1 (ko) 2010-11-12 2020-07-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2670443A4 (en) 2011-01-31 2015-10-14 Univ Pennsylvania FOR NUCLEIC ACID MOLECULAR ENCODING NEW HERPES ANTIGENES, VACCINES THEREOF AND METHOD OF USE THEREOF
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
WO2012109668A1 (en) 2011-02-11 2012-08-16 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
US10081658B2 (en) 2011-04-25 2018-09-25 Advanced Bioscience Laboratories, Inc. Truncated HIV envelope proteins (ENV), methods and compositions related thereto
WO2012166493A1 (en) 2011-06-01 2012-12-06 Merial Limited Needle-free administration of prrsv vaccines
EP2731628B1 (en) 2011-07-11 2019-09-04 Inovio Pharmaceuticals, Inc. Dna vaccine against lassa virus
JP6084970B2 (ja) 2011-07-20 2017-02-22 メリアル インコーポレイテッド 最適化ネコ白血病ウイルスエンベロープ遺伝子を含む組換えネコ白血病ウイルスワクチン
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
CN103889450B (zh) 2011-10-12 2017-11-21 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
KR101868954B1 (ko) 2011-10-24 2018-07-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
JP6407028B2 (ja) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
EA026926B1 (ru) 2011-12-12 2017-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
HUE042396T2 (hu) 2012-03-20 2019-06-28 Merial Inc Mutáns C glikoproteint tartalmazó, rekombináns ló herpeszvírus-1 oltóanyag és alkalmazásai
EP2836505B1 (en) 2012-04-10 2019-01-23 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
KR20220140025A (ko) 2013-03-12 2022-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파밀로마 바이러스용 개선된 백신 및 이것을 사용하는 방법
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
ES2817903T3 (es) 2013-03-15 2021-04-08 Univ Pennsylvania Proteínas de consenso del virus de la Fiebre Aftosa (VFA), secuencias codificantes y vacunas preparadas a partir de las mismas
CA2943816A1 (en) 2014-04-03 2015-10-08 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
ES2902491T3 (es) 2015-06-23 2022-03-28 Boehringer Ingelheim Animal Health Usa Inc Vectores virales recombinantes que contienen una proteína menor de PRRSV y procedimientos de fabricación y uso de los mismos
JP7046607B2 (ja) 2015-08-31 2022-04-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 先天性振戦に対するペスチウイルスワクチン
WO2017048677A1 (en) 2015-09-16 2017-03-23 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
TW201823465A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 新穎豬流感疫苗
NZ751966A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters
AU2017332677B2 (en) 2016-09-20 2024-01-11 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
MY199743A (en) 2016-09-20 2023-11-21 Boehringer Ingelheim Vetmedica Gmbh Ehv insertion site orf70
RS67051B1 (sr) 2016-11-03 2025-08-29 Boehringer Ingelheim Vetmedica Gmbh Vakcina protiv svinjskog parvovirusa
MX380632B (es) 2016-11-03 2025-03-12 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio y reproductivo porcino y métodos de producción de esta.
JP2020506915A (ja) 2017-01-30 2020-03-05 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド ブタコロナウイルスワクチン
MX421268B (es) 2017-07-12 2025-03-14 Boehringer Ingelheim Animal Health Usa Inc Composiciones inmunogenas de senecavirus a y metodos de estas
EP3675903A1 (en) 2017-09-23 2020-07-08 Boehringer Ingelheim Vetmedica GmbH Paramyxoviridae expression system
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
MX2020006226A (es) 2017-12-13 2020-11-18 Inovio Pharmaceuticals Inc Vacunas contra el cancer dirigidas a mesotelina y usos de estas.
KR102756354B1 (ko) 2017-12-13 2025-01-21 이노비오 파마수티컬즈, 인크. Prame를 표적으로 하는 암 백신 및 이의 용도
CA3084135C (en) 2017-12-13 2024-03-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
KR102668476B1 (ko) 2017-12-13 2024-05-23 이노비오 파마수티컬즈, 인크. Boris를 표적으로 하는 암 백신 및 이의 용도
RU2711907C2 (ru) * 2017-12-22 2020-01-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Рекомбинантный белок, содержащий антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (варианты)
CA3088646A1 (en) 2018-02-23 2019-08-29 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
US11596681B2 (en) 2018-03-19 2023-03-07 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
JP7273840B2 (ja) 2018-03-19 2023-05-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 不活性化ｕｌ１８および／またはｕｌ８を有する新しいｅｈｖ
JP7162072B2 (ja) 2018-03-26 2022-10-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 免疫原性組成物を製造する方法
CN112867506B (zh) 2018-09-20 2025-08-05 勃林格殷格翰动物保健有限公司 抗猪流行性腹泻的鼻内载体疫苗
JP7284822B2 (ja) 2018-09-20 2023-05-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 改変ｐｅｄｖスパイクタンパク質
CN115768784A (zh) 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
MX2023004006A (es) 2020-10-05 2023-04-26 Boehringer Ingelheim Vetmedica Gmbh Proteina fusion util para la vacunacion contra el rotavirus.
AU2023251268A1 (en) 2022-04-05 2024-11-14 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061898A (en) 1963-03-07 1967-03-15 Philips Electronic Pharma Method for protecting dogs against canine distemper
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
AU570940B2 (en) * 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
EP0162738A1 (en) 1984-04-09 1985-11-27 MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP Production of pseudorabies virus subunit vaccines
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
EP0284416B1 (en) * 1987-03-27 1995-02-22 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
EP0297924A3 (en) * 1987-07-01 1990-07-11 City Of Hope Recombinant vaccinia virus expressing hsv 1 gb
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1990001546A1 (en) * 1988-08-05 1990-02-22 Applied Biotechnology, Inc. Equine herpesvirus-1 vaccine
IE71643B1 (en) 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper

Also Published As

Publication number Publication date
GB9120655D0 (en) 1991-11-27
GB2246784B (en) 1993-04-28
IT1241119B (it) 1993-12-29
JP2000157292A (ja) 2000-06-13
CA2014465A1 (en) 1990-10-17
KR920700289A (ko) 1992-02-19
JPH04505248A (ja) 1992-09-17
JP3246735B2 (ja) 2002-01-15
DK174391A (da) 1991-12-12
IE901380L (en) 1990-10-17
AU5552090A (en) 1990-11-16
LU88018A1 (fr) 1992-03-11
CA2014465C (en) 1999-06-15
DE4090565C2 (de) 2000-03-09
DK174391D0 (da) 1991-10-15
ATA902590A (de) 1998-10-15
GB2246784A (en) 1992-02-12
IE61098B1 (en) 1994-09-21
FR2647808A1 (fr) 1990-12-07
JP3083839B2 (ja) 2000-09-04
IT9020063A1 (it) 1991-10-17
US5338683A (en) 1994-08-16
NL9020677A (nl) 1992-02-03
AT405184B (de) 1999-06-25
NL195016C (nl) 2003-06-10
DK176464B1 (da) 2008-03-31
BE1004369A5 (fr) 1992-11-10
FR2647808B1 (fr) 1995-03-03
WO1990012882A1 (en) 1990-11-01
US6183750B1 (en) 2001-02-06
AU625623B2 (en) 1992-07-16
IT9020063A0 (it) 1990-04-17
CH682671A5 (fr) 1993-10-29
US5482713A (en) 1996-01-09

Similar Documents

Publication Publication Date Title
FR2644892B1 (show.php)
DE4090565T (show.php)
DE4090852T (show.php)
IN175696B (show.php)
FR2643427B1 (show.php)
FR2643306B1 (show.php)
FR2653389B1 (show.php)
EP0436814A3 (show.php)
FR2642492B1 (show.php)
DE4090195T (show.php)
FR2644169B1 (show.php)
DE4091546T (show.php)
FR2643671B1 (show.php)
US5030857B1 (show.php)
FR2645838B1 (show.php)
FR2643457B1 (show.php)
DE4090226T (show.php)
FR2644153B1 (show.php)
FR2645491B1 (show.php)
FR2643690B1 (show.php)
FR2645047B1 (show.php)
DE4090092T (show.php)
FR2643929B1 (show.php)
FR2641957B1 (show.php)
FR2642746B1 (show.php)